Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in

Updated 06/14/2024

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00162136
Study type	Interventional
Source	R-Pharm
Contact
Status	Completed
Phase	Phase 1
Start date	September 2005
Completion date	July 2008

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01202370` - A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies	Phase 1
	Recruiting	`NCT05006794` - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies	Phase 1
	Active, not recruiting	`NCT02537418` - Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens	Phase 1
	Completed	`NCT01540526` - Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib	Phase 1
	Completed	`NCT00033202` - This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor	Phase 1
	Recruiting	`NCT04492735` - The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
	Completed	`NCT05866354` - To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies	Phase 1
	Completed	`NCT02640755` - Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase	Phase 1
	Terminated	`NCT00695370` - Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children	Phase 2
	Completed	`NCT02325739` - FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression	Phase 1/Phase 2
	Completed	`NCT00676299` - A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.	Phase 1
	Active, not recruiting	`NCT00090727` - Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	Phase 1
	Terminated	`NCT01112397` - Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours	Phase 1
	Not yet recruiting	`NCT00751894` - Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)	Phase 2